Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
P
208340
vs
K
KOSPI 200
Over the past 12 months, PharmAbcine Inc has underperformed KOSPI 200, delivering a return of 0% compared to KOSPI 200's +53% growth.
Stocks Performance
208340 vs KOSPI 200
Performance Gap
208340 vs KOSPI 200
Performance By Year
208340 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
PharmAbcine Inc
Glance View
PharmAbcine Inc. engages in the development of human therapeutic monoclonal antibody (mAb) for the treatment of cancer and inflammatory diseases. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2018-11-21. The firm researching and developing antibody therapeutics to provide patients with the antibodies needed to cure the disease. The Company’s major products include tanibirumab used for cancer treatment, among others. The firm also carries out technology transfer about its pipelines with domestic and overseas pharmaceutical companies.